HCW Biologics Inc. reported financial results for Q3 2025, aiming to dose the first patient in a Phase 1 clinical study for HCW9302, a treatment for autoimmune diseases. The company also seeks a commercial partner for its T-cell engager compounds and issued shares for gross proceeds of $2.2 million in Q3.

The company opened two clinical sites for a Phase 1 trial of HCW9302 in patients with alopecia areata, a common autoimmune disease. They also presented data on HCW11-018b and HCW11-040, highlighting their TCE and immune checkpoint inhibitor programs. Revenues were $15,606 for Q3 2025, with R&D expenses at $1.4 million.

HCW Biologics faces financial challenges, with a net loss of $4.6 million for Q3 2025. The company seeks additional funding to continue operations, aiming to access public markets for securities sales. Compliance with Nasdaq listing rules is essential for continued listing. The Company’s TRBC platform holds promise for developing immunotherapeutics for various diseases.

Read more at Globe Newswire: HCW Biologics Reports Third Quarter 2025 Business